Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular, cancer
- Who it enrolls
- age 18 Years to no upper limit; male; excludes diabetes; no BMI minimum stated; conditions: Prostate Cancer
- Interventions
- Semaglutide Pen Injector
- Conditions
- Prostate Cancer
- Phase and size
- Phase 4 · 20 participants
- Dates
- Start 2025-07-02
Primary completion 2026-07-31 - Sponsor
- Hamilton Health Sciences Corporation (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Number of Serious Adverse Events12 months
- Number of Adverse Events leading to Drug Discontinuation6 months
- Measure of Weight12 months
- Measure of Waist Circumference12 months
- Measure of Blood Pressure12 months
- Concentration of HbA1c12 months
- Concentration of Lipids12 months
- Concentration of PSA12 months
- Concentration of Creatinine12 months
- Calculation of estimated glomerular rate12 months
- Number of Clinical Outcomes12 months
02Eligibility
Who can take part
Inclusion Criteria: * Have a physician diagnosis of PC * Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor) * Elevated BMI 1. ≥30kg/m2 or 2. ≥27kg/m2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia Exclusion Criteria: * Type 1 diabetes * Taking a GLP-1 RA * \<18 years of age * History of pancreatitis * Personal or family history of medullary cancer of the thyroid * Multiple endocrine neoplasia type 2
03Change log
Registry changes
No changes recorded since the trial was added.